Literature DB >> 16786332

Chronic lithium chloride administration to rats elevates glucose metabolism in wide areas of brain, while potentiating negative effects on metabolism of dopamine D2-like receptor stimulation.

Mireille Basselin1, Lisa Chang, Stanley I Rapoport.   

Abstract

RATIONALE AND
OBJECTIVES: The regional cerebral metabolic rate for glucose (rCMRglc) can be imaged in vivo as a marker of brain functional activity. The effects of chronic lithium administration on baseline values of rCMRglc and values in response to administration of dopamine D2-like receptor agonists have not been examined in humans or rats. Knowing these effects may elucidate and localize the therapeutic action of lithium in bipolar disorder.
METHODS: In unanesthetized rats, we used the 2-deoxy-D-glucose (2-DG) technique to image the effects of a 6-week control diet or LiCl diet sufficient to produce a plasma lithium concentration therapeutically relevant to bipolar disorder, on rCMRglc at baseline and in response to the dopaminergic D2-like receptor agonist, quinpirole (1 mg/kg i.v.), or to i.v. saline.
RESULTS: Baseline rCMRglc was significantly elevated in 30 of 81 brain regions examined, in LiCl diet compared with control diet rats. Affected were visual and auditory structures, frontal cortex, amygdala, hippocampus, nucleus accumbens, caudate-putamen, interpeduncular nucleus, and substantia nigra. Acute quinpirole significantly decreased rCMRglc in four areas of the caudate-putamen in control diet rats, and in these and 19 additional brain areas in LiCl-fed rats.
CONCLUSIONS: In unanesthetized rats, chronic lithium administration widely upregulates baseline rCMRglc and potentiates the negative effects on rCMRglc of D2-like receptor stimulation. The baseline elevation may relate to lithium's reported ability to increase auditory and visual evoked responses in humans, whereas lithium's potentiation of quinpirole's negative effects on rCMRglc may be related to its therapeutic efficacy in bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786332     DOI: 10.1007/s00213-006-0425-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

1.  Differences in quinpirole-induced local cerebral glucose utilization between naive and sensitized rats.

Authors:  Toni L Carpenter; Thomas L Pazdernik; Beth Levant
Journal:  Brain Res       Date:  2003-02-28       Impact factor: 3.252

2.  Multisensory responses and receptive field properties of neurons in the substantia nigra and in the caudate nucleus.

Authors:  Attila Nagy; Zsuzsanna Paróczy; Masao Norita; György Benedek
Journal:  Eur J Neurosci       Date:  2005-07       Impact factor: 3.386

3.  Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.

Authors:  F J Ehlert; L P Tran
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

4.  Temporal dynamics of cortical and subcortical responses to apomorphine in Parkinson disease: an H2(15)O PET study.

Authors:  Lara A Hosey; Jennifer L W Thompson; Leonard Verhagen Metman; Pepyn van den Munckhof; Allen R Braun
Journal:  Clin Neuropharmacol       Date:  2005 Jan-Feb       Impact factor: 1.592

Review 5.  New strategies with dopaminergic drugs: modified formulations of levodopa and novel agonists.

Authors:  C G Goetz
Journal:  Exp Neurol       Date:  1997-03       Impact factor: 5.330

6.  Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration.

Authors:  Francesca Bosetti; Ruth Seemann; Jane M Bell; Robert Zahorchak; Elliott Friedman; Stanley I Rapoport; Pachiappan Manickam
Journal:  Brain Res Bull       Date:  2002-01-15       Impact factor: 4.077

7.  Time-course and regional distribution of the metabolic effects of bromocriptine in the rat brain.

Authors:  G Pizzolato; T T Soncrant; S I Rapoport
Journal:  Brain Res       Date:  1985-08-26       Impact factor: 3.252

8.  Effect of valproate on cerebral metabolism and blood flow: an 18F-2-deoxyglucose and 15O water positron emission tomography study.

Authors:  W D Gaillard; T Zeffiro; S Fazilat; C DeCarli; W H Theodore
Journal:  Epilepsia       Date:  1996-06       Impact factor: 5.864

9.  Tomographic mapping of human cerebral metabolism visual stimulation and deprivation.

Authors:  M E Phelps; J C Mazziotta; D E Kuhl; M Nuwer; J Packwood; J Metter; J Engel
Journal:  Neurology       Date:  1981-05       Impact factor: 9.910

Review 10.  Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets.

Authors:  Paul J Carlson; Jaskaran B Singh; Carlos A Zarate; Wayne C Drevets; Husseini K Manji
Journal:  NeuroRx       Date:  2006-01
View more
  7 in total

1.  Is phosphoadenosine phosphate phosphatase a target of lithium's therapeutic effect?

Authors:  G Shaltiel; J Deutsch; S I Rapoport; M Basselin; R H Belmaker; G Agam
Journal:  J Neural Transm (Vienna)       Date:  2009-11       Impact factor: 3.575

Review 2.  Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade.

Authors:  Stanley I Rapoport
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

Review 3.  Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.

Authors:  Mireille Basselin; Epolia Ramadan; Stanley I Rapoport
Journal:  Brain Res Bull       Date:  2011-12-09       Impact factor: 4.077

4.  Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions.

Authors:  Teresa W-M Fan; Peixiong Yuan; Andrew N Lane; Richard M Higashi; Yun Wang; Anahita B Hamidi; Rulun Zhou; Xavier Guitart; Guang Chen; Husseini K Manji; Rima Kaddurah-Daouk
Journal:  Metabolomics       Date:  2010-06-01       Impact factor: 4.290

Review 5.  Bipolar disorder and mechanisms of action of mood stabilizers.

Authors:  Stanley I Rapoport; Mireille Basselin; Hyung-Wook Kim; Jagadeesh S Rao
Journal:  Brain Res Rev       Date:  2009-06-23

6.  Mesocortical BDNF signaling mediates antidepressive-like effects of lithium.

Authors:  Di Liu; Qian-Qian Tang; Di Wang; Su-Pei Song; Xiao-Na Yang; Su-Wan Hu; Zhi-Yong Wang; Zheng Xu; He Liu; Jun-Xia Yang; Sarah E Montgomery; Hongxing Zhang; Ming-Hu Han; Hai-Lei Ding; Jun-Li Cao
Journal:  Neuropsychopharmacology       Date:  2020-05-19       Impact factor: 7.853

7.  Pharmacometabolomic signature of ataxia SCA1 mouse model and lithium effects.

Authors:  Bertrand Perroud; Paymaan Jafar-Nejad; William R Wikoff; Jennifer R Gatchel; Lu Wang; Dinesh K Barupal; Juan Crespo-Barreto; Oliver Fiehn; Huda Y Zoghbi; Rima Kaddurah-Daouk
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.